Clinical trials: Type1 Diabetes
- Condition Type1 Diabetes
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Diabetes Mellitus, Type 1
The PSIQS Study - User Experience With Pro-Set
Open label, randomized 2-period cross-over study comparing two continuous subcutaneous insulin infusion sets ; MiniMed® Pro-set® with BD FlowSmart™ technology and MiniMed® Quick-set®
- Trial name
- NCT03242005
- Testing
- MiniMed® Pro-set®, MiniMed® Quick-set®
- Sponsor
- Becton, Dickinson and Company
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00671008
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- Bosnia and Herzegovina
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients…
- Trial name
- NCT00920582
- Testing
- Teplizumab Herold Regimen, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
- Where
- 118 sites in United States, Belgium and 14 more
- Volunteers
- 254 people
- Sponsor
- MacroGenics
Type 1 Diabetes, Type 2 Diabetes
A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port
This study investigated wearability and usability of the I-PORT™ Injection Port (I-PORT™), a new disposable injection port through which prescribed medication is injected subcutaneously from a standard syringe or pen.
- Trial name
- NCT00486109
- Testing
- I-Port(TM) Injection Port
- Where
- 5 sites in United States
- Volunteers
- 74 people
- Sponsor
- Patton Medical Devices
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5/Simplera Sync in people with diabetes.
- Trial name
- NCT07228117
- Testing
- MiniMed™ NMX8-AID System with DS5™/Simplera Sync™
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 389 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 640G Insulin Pump
This four center international study will include two United Kingdom National Health Service centers, and two centers in Melbourne, Australia.
- Trial name
- NCT01991548
- Testing
- MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus ( Type 1 and Type 2)
Actions & Insights Evaluating a Novel Diabetes Management Solution
Single visit outcome study to obtain qualitative and quantitative data for a new BGMS.
- Trial name
- ASCEND (NCT03638349)
- Where
- 3 sites in United Kingdom
- Volunteers
- 163 people
- Sponsor
- LifeScan Scotland Ltd
Diabetes Mellitus, Type 1
Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.
- Trial name
- NCT00479258
- Testing
- Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes
Many people with diabetes have a desire to share blood glucose data with other members of their team. Using a unique wireless glucose meter device, real-time wireless alerts may be automatically sent to a specific team of…
- Trial name
- NCT00322478
- Testing
- Automated informatics driven education and social networking, Blood Glucose Notifications to Remote Caregivers, Frequency of Pattern Management
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Diabetech
Diabetes, Diabetes Mellitus, Type 1
Observational Study on Levemir® in Obese Diabetic Patients
This study is conducted in Europe. The aim of this observational study is to investigate the effect of switch from other basal insulin treatments to Levemir® on body weight in obese diabetic patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- KILOS (NCT00849342)
- Testing
- insulin detemir
- Where
- 2 sites in Netherlands, Slovenia
- Volunteers
- 580 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System
This study is a Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects.
- Trial name
- NCT03959423
- Testing
- AHCL insulin pump system
- Where
- 17 sites in United States
- Volunteers
- 288 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast…
- Trial name
- NCT00046501
- Testing
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Changing Diabetes® World Tour
This study is conducted in the Middle East, Northern Africa and Europe. The aim of this study is to contribute to the design of a simple screening strategy for countries in scope, by exploring the association between risk factors…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01437072
- Testing
- No treatment given
- Where
- 3 sites in Portugal, Saudi Arabia and 1 more
- Volunteers
- 8,304 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)
This clinical trial will explore the safety and effect of autologous ex vivo expanded polyclonal regulatory T-cells on beta cell function in patients, aged 8 to 17, with recent onset T1DM.
- Trial name
- NCT02691247
- Testing
- CLBS03 Low Dose, CLBS03 High Dose
- Where
- 15 sites in United States
- Volunteers
- 113 people
- Sponsor
- Lisata Therapeutics, Inc.
Type 1 Diabetes Mellitus
Pediatric Diabetics Type 1 Using InsuPatch
This study is a prospective, single-center, open label, randomized; two-arms cross over study. This is the test protocol for the InsuPatch device, whose purpose is to improve insulin delivery into the blood when the insulin is…
- Trial name
- NCT01368978
- Testing
- InsuPatch
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Insuline Medical Ltd.
Type 1 Diabetes Mellitus
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT
The intended purpose of this study was to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
- Trial name
- NCT00751842
- Testing
- rhGAD65
- Where
- 43 sites in United States
- Volunteers
- 331 people
- Sponsor
- Diamyd Therapeutics AB
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
PS230005 Control-IQ 1.5 Post-Approval Study
This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to <6 years old.
- Trial name
- NCT06717451
- Testing
- Control-IQ Technology v1.5
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Tandem Diabetes Care, Inc.